Possible mechanisms of action of valproic acid in myoclonus
Van Woert, M.H.; Chung, E.Y.
Advances in Neurology 43: 653-660
1986
ISSN/ISBN: 0091-3952 PMID: 2418654 Document Number: 279866
Document emailed within 1 workday
Related Documents
Pratt, J.A.; Rothwell, J.; Jenner, P.; Marsden, C.D. 1986: P,p'-DDT-induced myoclonus in the rat and its application as an animal model of 5-HT-sensitive action myoclonus Advances in Neurology 43: 577-588Youle, R J. 2003: Haya Lorberboum-Galski and Philip Lazarovici (Eds.). Chimeric Toxins: Mechanisms of Action and Therapeutic Applications (Cell and Molecular Mechanisms of Toxin Action) International Journal of Toxicology 22(4): 331-332
Porubek, D.J.; Grillo, M.P.; Baillie, T.A. 1989: The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes Drug Metabolism and Disposition: the Biological Fate of Chemicals 17(2): 123-130
Champel, V.; Radal, M.; Moulin-Vallez, M.; Jonville-Béra, A.P.; Autret-Leca, E. 1999: Should folic acid be given to women treated with valproic acid and/or carbamazepine? Folic acid and pregnancy in epilepsy Revue Neurologique (Paris) 155(3): 220-224
Poliakovskiĭ, S.A.; Kravchuk, Z.N.; Dmitriev, A.P. 2008: Mechanisms of action of plant resistance inductor beta-aminobutyric acid in Allium cepa Tsitologiia i Genetika 42(6): 8-12
Liu, M.J.; Brouwer, K.L.; Pollack, G.M. 1992: Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat Drug Metabolism and Disposition: the Biological Fate of Chemicals 20(6): 810-815
Wolfe, S.E.; Brostrom, C.O.; Brostrom, M.A. 1986: Mechanisms of action of inhibitors of prolactin secretion in GH3 pituitary cells. I. Ca2+-dependent inhibition of amino acid incorporation Molecular Pharmacology 29(4): 411-419
Kohda, Y. 1995: Valproic acid Nihon Rinsho. Japanese Journal of Clinical Medicine 53 Su Pt 1: 918-920
Waring, E.W.; Dewan, V.K.; Cohen, D.; Grewal, R. 1999: Risperidone as an adjunct to valproic acid Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 44(2): 189
Gedan, A.; Kleemann, V.; Pfeifer, S. 1984: Hydrolysis of valproamide to valproic acid Die Pharmazie 39(12): 865
Borchert, H.H.; Schuster, S.; Pfeifer, S. 1980: Metabolic interaction of valproic acid Die Pharmazie 34(5-6): 313-314
Klotz, U. 1977: Pharmacokinetic studies with valproic acid in man Arzneimittel-Forschung 27(5): 1085-1088
Kohda, Y. 1990: Therapeutic drug monitoring of valproic acid Nihon Rinsho. Japanese Journal of Clinical Medicine 48 Suppl: 1130-1133
Michaelis, M.; Doerr, H.W.; Cinatl, J. 2007: Valproic acid as anti-cancer drug Current Pharmaceutical Design 13(33): 3378-3393
Bruni, J.; Wilder, B.J.; Willmore, L.J.; Barbour, B. 1979: Valproic acid and plasma levels of phenytoin Neurology 29(6): 904-905
Tonnelier, J.M.; Mocquard, Y.; Broch, C.; Vandhuick, O.; Goas, P.; Goas, J.Y. 2001: Febrile pleuropericarditis during valproic acid treatment Presse Medicale 30(2): 62-63
Franke, G.; Diletti, E.; Hoffmann, C.; Zschiesche, M.; Scheuch, E.; Siegmund, W. 1995: Relative bioavailability of different valproic acid formulations International Journal of Clinical Pharmacology and Therapeutics 33(12): 653-657
Vajda, F.J. 1983: Valproic acid in the treatment of status epilepticus Advances in Neurology 34: 519-529
Löscher, W. 1981: Anticonvulsant activity of metabolites of valproic acid Archives Internationales de Pharmacodynamie et de Therapie 249(1): 158-163
Garden, A.S.; Benzie, R.J.; Hutton, E.M.; Gare, D.J. 1985: Valproic acid therapy and neural tube defects Canadian Medical Association Journal 132(8): 933; 936